Globus Medical (NYSE:GMED) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

Globus Medical, Inc. (NYSE:GMED)’s stock price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $83.35 and traded as high as $87.38. Globus Medical shares last traded at $87.0360, with a volume of 2,349,740 shares trading hands.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Wall Street Analysts Forecast Growth

GMED has been the subject of several recent analyst reports. Needham & Company LLC lowered their price objective on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research note on Friday. Royal Bank Of Canada reduced their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Truist Financial cut their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Finally, BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.46.

Globus Medical Price Performance

The stock’s fifty day moving average is $77.20 and its 200-day moving average is $83.18. The stock has a market cap of $9.49 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 1.28 and a beta of 0.98.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. During the same quarter in the previous year, the business posted $1.18 earnings per share. The business’s quarterly revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts expect that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Insider Transactions at Globus Medical

In related news, Director James Tobin sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. The trade was a 66.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of Globus Medical stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 60,000 shares of company stock valued at $4,838,400 in the last three months. 18.38% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GMED. Janus Henderson Group PLC increased its holdings in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares during the period. Sculptor Capital LP raised its stake in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Globus Medical by 14.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after purchasing an additional 225,534 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after acquiring an additional 33,976 shares during the last quarter. Finally, Boston Trust Walden Corp lifted its stake in shares of Globus Medical by 4.4% during the third quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock valued at $123,071,000 after acquiring an additional 69,782 shares during the period. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.